NYSE:PTHS
Pelthos Therapeutics Inc.
A pre-revenue biotech firm targeting rare disease indications with a cash runway that requires ongoing capital raising to sustain R&D operations.
Key Metrics
Investment Thesis
Bull Case
Investors might consider this stock if they believe the management team can secure strategic partnerships or successful licensing deals for its rare disease assets before cash runs out, potentially creating a turnaround story where current market cap reflects extreme downside but offers high upside upon commercialization.
Bear Case
The stock is unattractive due to negative net profit of -$8.0M, zero revenue, and a current liability load of $4.1M against only $1.4M in current assets, suggesting the company may not survive without immediate external funding or asset sales.
About Pelthos Therapeutics Inc.
Pelthos Therapeutics (NYSE: PTHS) is a biotechnology company focused on developing novel therapeutics for rare diseases, leveraging proprietary platforms to address unmet medical needs in underserved markets.
Analysis
Management Discussion
Recent financial performance reflects deep losses with net income at -$8.0M in 2024 compared to -$7.4M previously, driven by operating expenses of $7.6M including $1.8M in share-based compensation. The cash position deteriorated significantly from a beginning balance of $96.4M to an ending balance of just $513k, indicating severe liquidity pressure despite recent financing efforts.
Industry Overview
The rare disease therapeutics sector is characterized by high failure rates but offers significant rewards for successful launches, yet it remains capital intensive with most companies like Pelthos operating at a loss until product approval and commercialization occur.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2023 | 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Cost of Revenue | $0 | $0 |
| Gross Profit | $0 | $0 |
| Operating Expenses | $6.9M | $7.6M |
| Operating Income | $-6.9M | $-7.6M |
| R&D | $2.6M | $1.2M |
| G&A | $2.7M | $4.1M |
| Stock-Based Comp | $1.7M | $1.8M |
| Other OpEx | $1.5M | $2.3M |
| Non-Operating Income | $-518.5K | $0 |
| Pre-Tax Income | $-7.4M | $-7.6M |
| Income Tax | $0 | $383.9K |
| Continuing Ops | $-7.4M | $-8.0M |
| Discontinued Ops | $0 | $0 |
| Net Income | $-7.4M | $-8.0M |
| Minority Interest | $0 | $0 |
| Net to Common | $-7.4M | $-8.0M |
| Metric | 2023 | 2024 |
|---|---|---|
| Current Assets | $96.4K | $1.4M |
| Cash & Equivalents | $100.0K | — |
| Other Current Assets | $-3.6K | — |
| Long-Term Assets | $0 | $0 |
| Total Assets | $96.4K | $1.4M |
| Current Liabilities | $6.5M | $4.1M |
| Other Current Liab | $5.9M | — |
| Long-Term Liabilities | $0 | $0 |
| Total Liabilities | $6.5M | $4.1M |
| Shareholders' Equity | $-6.4M | $-2.7M |
| Paid-In Capital | $7.1M | $18.8M |
| Retained Earnings | $-13.5M | $-21.5M |
| Total L&E | $96.4K | $1.4M |
| Metric | 2023 | 2024 |
|---|---|---|
| Net Income (CFO) | $-7.4M | $-8.0M |
| Non-Cash Adjustments | $4.3M | $451.8K |
| Working Capital Changes | $2.1M | $1.7M |
| Cash from Operations | $-981.0K | $-5.8M |
| Cash from Investing | $0 | $0 |
| Share Buybacks | — | $75.0K |
| Cash from Financing | $1.0M | $6.2M |
| FX Effect | $0 | $0 |
| Net Change in Cash | $41.3K | $417.1K |
| Beginning Cash | $55.1K | $96.4K |
| Ending Cash | $96.4K | $513.4K |
Frequently Asked Questions
How does Pelthos Therapeutics Inc. make money?
The company operates primarily through its research and development segment focused on drug discovery for orphan drugs, with current financials showing zero revenue and operating expenses dominated by general and administrative costs ($4.1M) and research and development spending ($1.2M).
What are the main risks for PTHS?
The company faces significant risk of dilution from common share issuances ($6.0M in financing activity) needed to offset negative cash flow from operations (-$5.8M), a substantial retained earnings deficit of -$21.5M, and the high probability of clinical trial failure for its early-stage pipeline.
What is PTHS's competitive advantage?
Pelthos differentiates itself through a specialized focus on rare diseases where competition is limited, potential for high pricing power due to orphan drug exclusivity, and the ability to partner with larger pharmaceutical companies seeking late-stage assets.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.